Mdxhealth SA has received a notification from The Nasdaq Stock Market LLC indicating it is not in compliance with the minimum bid price requirement for continued listing. The company has been granted 180 calendar days, or until December 28, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). This development does not immediately impact the company's listing on The Nasdaq Capital Market.

The notification, dated June 30, 2026, was issued by the Listing Qualifications Department of The Nasdaq Stock Market LLC. It cites a failure to meet the minimum bid price set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of US$1.00 per share. The press release was issued pursuant to Nasdaq Listing Rule 5810(b), which mandates prompt disclosure upon receipt of such a deficiency notification.

Under the provisions of Nasdaq Listing Rule 5810(c)(3)(A), Mdxhealth SA has the specified 180-day period to cure the deficiency. To regain compliance, the company must achieve a minimum closing bid price of US$1.00 per share for at least ten consecutive business days. If compliance is not achieved by the deadline, the company may be subject to delisting proceedings, though it may be eligible for additional time or may pursue other remedial measures provided by Nasdaq rules.

The company stated that its business operations are not affected by the receipt of the Notification Letter. Mdxhealth SA intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options, including a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

MDXHealth announced the peer-reviewed publication of the Oxford GPS-ProMPT study in the journal European Urology Oncology. The publication marks the first major peer-reviewed milestone from the collaboration with the University of Oxford. It serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study, which has the potential to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence in localized prostate cancer.

Michael K. McGarrity, Chief Executive Officer of mdxhealth, stated that the acceptance of Professor Freddie Hamdy’s GPS-ProMPT study is an important milestone. He noted that the findings provide the scientific foundation for the ongoing GPS-ProtecT study. McGarrity added that the publication supports the advancement of GPS regarding guideline development, payer coverage, and physician adoption.

Lead author Dr Nikita Sushentsev from Cambridge University Hospitals NHS Foundation of Trust commented on the findings. The ProMPT findings demonstrate that patients with favorable GPS mdx scores achieved excellent long-term outcomes. This includes 92% freedom-from-failure at six years in active surveillance and up to 100% in surgery and radiotherapy cohorts. These results were observed even among patients with adverse clinical risk factors.

The study suggests that GPS mdx can identify favorable tumor biology that traditional risk stratification alone would miss. This has meaningful implications for how physicians counsel patients facing treatment decisions. The publication is expected to influence future guideline development and payer coverage for genomic classifiers in prostate cancer.